je.st
news
Tag: lung
GSK and Theravance Announce Start of Phase III Lung Function Study...
2015-02-10 06:04:15| Biotech - Topix.net
Enrolling approximately 1,800 patients, the FULFIL study will assess whether the inhaled corticosteroid, long-acting muscarinic antagonist and long-acting beta2-adrenergic agonist combination, all delivered in GSK's ElliptaA inhaler, can improve lung function and health-related quality of life compared with budesonide/formoterol, a twice-daily ICS/LABA combination delivered via the TurbohalerA dry powder inhaler. Secondary objectives include investigating the effect on the rate of exacerbations with FF/UMEC/VI compared with budesonide/formoterol, and the safety profile of FF/UMEC/VI compared with budesonide/formoterol.
Tags: start
study
iii
function
HEI ACES study of lifetime animal exposure to New Technology Diesel Engine exhaust finds no lung cancer
2015-01-27 11:55:40| Green Car Congress
Tags: technology
study
engine
animal
Patient Management System aids lung cancer screening.
2014-12-09 14:30:52| Industrial Newsroom - All News for Today
With Patient Management Solution, health care providers can implement and manage comprehensive CT lung screening program which tracks and guides patients across health continuum. Solution integrates consultative services and marketing support; patient management software tools for 360° view of patients; radiology software tools which facilitate review and reporting of serial CT lung exams; and online education portal to measure and report radiologist performance.
Tags: system
management
aids
cancer
50M Investment To Develop Lung Cancer Drugs
2014-12-03 07:11:19| drugdiscoveryonline News Articles
The Cancer Research Technology Pioneer Fund (CPF) recently (Friday) has announced a collaboration with the Cancer Research UK Manchester Institute Drug Discovery Unit, at The University of Manchester, to develop a promising class of drugs called RET inhibitors to treat cancer
Tags: develop
investment
cancer
drugs
Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
2014-10-27 11:45:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of patients with Epidermal Growth Factor Receptor (EGFR) mutation-negative, and Anaplastic Lymphoma Kinase (ALK) rearrangement-negative non-small cell lung cancer (NSCLC) whose disease has progressed on or following platinum-based chemotherapy. Language: English Contact: Media Contacts:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestor Contacts:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
cell
cancer
therapy
Sites : [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] next »